No. 1 is SCBGENOME(SSFE) +55.13%
กองทุนเปิด แอล เอช เฮลธ์ อินโนเวชั่น ชนิดเพื่อการออมและจ่ายเงินปันผล
Shows where this fund stands in its group. Not investment advice · Data as of 12 Nov 2026
LHHEALTH-DSSF invests through the master fund AB International Health Care Portfolio 96.78%
This fund and the master fund each charge their own fees. See the fees section of this page for the actual fees
Fact sheet checked on 2 Nov 2026 · Top 6 shown, the rest grouped as Other · per AllianceBernstein fact sheet
Over the past year it was below its group median; there is no rank for a longer period yet
| Return | MDD | |
|---|---|---|
| YTD | +14.16% | −9.34% |
| 1D | −0.39% | −0.39% |
| 1W | +1.33% | −0.43% |
| 2W | +1.32% | −2.72% |
| 1M | +9.43% | −2.72% |
| 3M | +8.17% | −6.24% |
| 6M | +19.71% | −6.24% |
| Return | SD | MDD | Return/SD | |
|---|---|---|---|---|
| 1Y | +14.96% | 16.36% | −9.34% | +0.91 |
| MAX | +17.84%+5.67%/yr | 14.43% | −24.18% | +0.39 |
No. 1 is SCBGENOME(SSFE) +55.13%
Each bar is one fund in the AIMC Health Care group, sorted from highest to lowest return · Only SSF share classes are counted, and only funds with a full track record for the period are included · Calculated from NAV as of
Past performance is not a guarantee of future results
Tap a year to see its months · * part year
Largest drawdown in the selected period −24.18% Previous peak 2 Sep 2024 (NAV 6.5465) → Trough 7 Aug 2025 (NAV 4.9635) · Back to the previous peak on 4 Nov 2026, after 1 year 2 months
Currently −1.24% from the peak NAV of 6.6635 (4 Nov 2026)
Over 1 year, LHHEALTH-DSSF returned 0.91 per unit of SD, ranking 8 of 12 funds · The highest is BCARESSF (1.46)
กองทุนมีนโยบายเน้นลงทุนในหน่วยลงทุนของกองทุนรวมต่างประเทศ (หรือ “กองทุนหลัก (Master fund)”) เฉลี่ยในรอบปีบัญชีไม่น้อยกว่าร้อยละ 80 ของมูลค่าทรัพย์สินสุทธิ Its largest holdings are Johnson & Johnson 9.74% · Eli Lilly & Co 9.44% · Merck & Co., Inc 6.43% (fact sheet 30 Oct 2026)
Risk level 7 of 8 (High risk). Since 20 Nov 2023, its NAV has fallen as much as −24.18% from its peak.
Actual total expense ratio (TER) 2.16% a year, against a ceiling of 5.00%. Management fee 1.61%. Front-end fee 0.00%. Back-end fee 0.00%. (Fact sheet 30 Sep 2026)
It has a dividend policy but has not paid any dividends yet
Minimum first purchase not set, subsequent purchases not set. Buy orders accepted until 14:00, sell orders until 14:00, and redemption proceeds are paid T+4
Hedged at the manager's discretion. As of 30 Sep 2026, 80.26% of the value of its foreign investments was hedged
They are share classes of the same fund and invest in the same assets. They differ only in each class's terms, such as dividend policy, fees or who can buy · LHHEALTH-DSSF: pays dividends, TER 2.16% · LHHEALTH-A: no dividends, TER 2.16% · LHHEALTH-ASSF: no dividends, TER 2.16% · LHHEALTH-D: pays dividends, TER 2.16% · LHHEALTH-E: no dividends, TER 2.16%
Warning Past performance is not a guarantee of future results · Investing involves risk. Investors should understand the product's features, return conditions and risks before making an investment decision · This fund invests abroad, so investors may lose or gain from exchange rate movements
An American medicines and medical devices company, with products such as cancer drugs and surgical instruments
Diabetes and weight-loss drugs
Hospitals, medicines and medical equipment
Hospitals, medicines and medical equipment
Hospitals, medicines and medical equipment
Based on the master fund's share of this fund's value (96.78% as of 30 Sep 2026) × each stock's weight in the master fund · fact sheet from AllianceBernstein · Illustrations are for explanation only, not individual stock recommendations
| ฿1,000 |
| LHHEALTH-ASSF | None | SSF | 2.16% | 0.00% | ฿0 |
| LHHEALTH-D | Pays | No | 2.16% | 1.25% | ฿1,000 |
| LHHEALTH-E | None | No | 2.16% | 0.00% | ฿500 |
| Return |
|---|
| MDD |
|---|
| SD |
|---|
| Return/SD |
|---|
| 1Y | +14.96% | −9.34% | 16.36% | +0.91 |
| MAX | +17.84%+5.67%/yr | −24.18% | 14.43% | +0.39 |